Bionano Genomics reported a significant decline in revenue for Q1 2025, with total revenue falling 26% year-over-year to $6.5 million. Despite the disappointing financial performance, Bionano’s ...

Bionano Genomics Inc. company and executive profile by Barron's. View the latest BNGO company infomation and executive bios.

Fintel reports that on September 10, 2024, BTIG downgraded their outlook for Bionano Genomics (NasdaqCM:BNGO) from Buy to Neutral. Analyst Price Forecast Suggests 1,351.68% Upside As of August 26 ...

Fintel reports that on August 28, 2024, Scotiabank downgraded their outlook for Bionano Genomics (NasdaqCM:BNGO) from Sector Outperform to Sector Perform. Analyst Price Forecast Suggests 1,250.89% ...

Bionano Genomics (BNGO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bionano Genomics, Inc. (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bionano Genomics, a company that develops technology for cancer research and diagnosis, is burning through cash at an unsustainable rate. Read more here.

Today, we circle back on an interesting diagnostic concern called Bionano Genomics, Inc. We have concerns for BNGO shareholders, click to see what they are.

Bionano Genomics (NASDAQ: BNGO) stock has taken its shareholders on a rollercoaster ride over the past couple of years. Right now, BNGO stock trades at around the same price as it did before its ...

High-flying growth stocks like Bionano Genomics (NASDAQ: BNGO) tend to be controversial among different crowds of investors. Where some might see a stock's potential to multiply in value over time ...

Bionano Genomics stock has had a rough 12 months. But its business model is still attractive due to its long-term recurring revenue potential. Developing new consumables and new devices will also ...